ESPERION THERAPEUTICS INC. - COMMON STOCK

Esperion to Report Third Quarter 2024 Financial Results on November 7

24 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire

Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

02 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

25 сен 2024 15:30:00 Источник Nasdaq GlobeNewswire

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

05 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)

03 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference

26 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update

12 авг 2024 05:00:00 Источник Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

07 авг 2024 15:30:00 Источник Nasdaq GlobeNewswire

Esperion to Report Second Quarter 2024 Financial Results on August 12

25 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire

Esperion to Participate in Upcoming BTIG Biotech Conference

24 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire

New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries

16 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire

Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

28 июн 2024 06:00:00 Источник Nasdaq GlobeNewswire

Esperion to Participate in Upcoming June Investor Conferences

23 май 2024 08:00:00 Источник Nasdaq GlobeNewswire

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

22 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

20 май 2024 05:00:00 Источник Nasdaq GlobeNewswire

Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®

14 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

10 май 2024 15:00:00 Источник Nasdaq GlobeNewswire

Esperion Reports First Quarter 2024 Financial Results

07 май 2024 05:00:00 Источник Nasdaq GlobeNewswire

Esperion to Participate in Upcoming May Investor Conferences

29 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire

Esperion to Report First Quarter 2024 Financial Results on May 7

23 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire